Premium
Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipients
Author(s) -
Franciosi Monica,
Caccamo Lucio,
De Simone Paolo,
Pinna Antonio Daniele,
Di Costanzo Giovanni Giuseppe,
Volpes Riccardo,
Scuderi Vincenzo,
Strignano Paolo,
Boccagni Patrizia,
Burra Patrizia,
Nicolucci Antonio
Publication year - 2012
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.22473
Subject(s) - medicine , hepatitis b immune globulin , cronbach's alpha , quality of life (healthcare) , liver transplantation , construct validity , hepatitis b , transplantation , feeling , gastroenterology , patient satisfaction , hepatitis b virus , immunology , psychometrics , surgery , clinical psychology , virus , psychology , social psychology , nursing , lamivudine
To date, there is still a lack of instruments for specifically assessing the impact of anti–hepatitis B virus prophylaxis after liver transplantation (LT) on health‐related quality of life (HRQOL) and treatment satisfaction. Focusing on the use of hepatitis B immune globulin (HBIG), we developed and validated the Immunoglobulin Therapy After Liver Transplantation Questionnaire (ITaLi‐Q), which includes 41 items and covers 5 domains (side effects, positive and negative feelings, impact on the flexibility of daily activities, support, and satisfaction). The questionnaire was tested by 177 consecutive LT patients [71.8% were male, 38.4% were more than 60 years old, 58.8% were on intramuscular (IM) HBIG, and 41.2% were on intravenous (IV) HBIG]. A factor analysis confirmed the hypothesized structure, and a multitrait, multi‐item analysis showed favorable psychometric characteristics for ITaLi‐Q: item‐scale correlations > 0.40 for all items but 1, high scaling success rates (>90% for all scales but 1), excellent internal consistency (Cronbach's α ≥ 0.8 for all scales), and good reproducibility (test‐retest coefficient > 0.70 for all scales but 2). ITaLi‐Q was able to discriminate between subgroups of patients according to their clinical and sociodemographic characteristics. In comparison with patients on IV HBIG, patients on IM HBIG reported significantly better HRQOL scores on the Flexibility (81.5 ± 21.4 versus 73.1 ± 24.2, P = 0.01) and Negative Feelings scales (90.1 ± 17.3 versus 85.4 ± 20.7, P = 0.04), but they reported worse HRQOL scores on the Side Effects scale (81.8 ± 22.8 versus 95.6 ± 7.4, P < 0.001). No differences were found between the route of HBIG administration and the Satisfaction, Positive Feelings, Impact, and Support scales. In conclusion, ITaLi‐Q showed adequate psychometric characteristics and revealed that the route of HBIG administration has a significant impact on specific HRQOL domains beyond a patient's satisfaction. Liver Transpl 18:332–339, 2012. © 2012 AASLD.